Standardized laboratory monitoring with use of isotretinoin in acne

Abstract

Laboratory monitoring for adverse effects to isotretinoin occurs with variability. Standardization of laboratory monitoring practices represents an opportunity to improve quality of care. We sought to develop an evidence-based approach to laboratory monitoring of patients receiving isotretinoin therapy for acne. We reviewed laboratory data from 515 patients with acne undergoing 574 courses of isotretinoin from March 2003 to July 2011. Frequency, timing, and severity of abnormalities were determined. Clinically insignificant leukopenia or thrombocytopenia occurred in 1.4% and 0.9% of patients, respectively. Elevated liver transaminases were detected infrequently and not significantly increased compared with baseline detection rates (1.9% vs 1.6% at baseline). Significant elevations occurred with triglyceride (19.3%) and cholesterol (22.8%) levels. The most severe abnormalities were grade 2 (moderate). Mean duration of treatment before abnormalities were detected was 56.3days for hypertriglyceridemia, 61.9days for alanine transaminitis, and 50.1days for hypercholesterolemia. This was a single-center experience examining variable isotretinoin laboratory monitoring practices. In healthy patients with normal baseline lipid panel and liver function test results, repeated studies should be performed after 2months of isotretinoin therapy. If findings are normal, no further testing may be required. Routine complete blood cell count monitoring is not recommended.